301 related articles for article (PubMed ID: 29600576)
21. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus.
Li J; Echevarria KL; Hughes DW; Cadena JA; Bowling JE; Lewis JS
Antimicrob Agents Chemother; 2014 Sep; 58(9):5117-24. PubMed ID: 24936596
[TBL] [Abstract][Full Text] [Related]
22. The Impact of Reporting a Prior Penicillin Allergy on the Treatment of Methicillin-Sensitive Staphylococcus aureus Bacteremia.
Blumenthal KG; Shenoy ES; Huang M; Kuhlen JL; Ware WA; Parker RA; Walensky RP
PLoS One; 2016; 11(7):e0159406. PubMed ID: 27438379
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of empirical antibiotic treatments in methicillin-susceptible Staphylococcus aureus infective endocarditis: A post hoc analysis of a prospective French cohort study.
Lecomte R; Deschanvres C; Bourreau A; Ruffier d'Epenoux L; Le Turnier P; Gaborit B; Chauveau M; Michel M; Le Tourneau T; Bémer P; Corvec S; Boutoille D
Int J Infect Dis; 2024 May; 142():106989. PubMed ID: 38428479
[TBL] [Abstract][Full Text] [Related]
24. Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.
Burrelli CC; Broadbent EK; Margulis A; Snyder GM; Gold HS; McCoy C; Mahoney MV; Hirsch EB
Chemotherapy; 2018; 63(6):345-351. PubMed ID: 30965335
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study.
Bai AD; Showler A; Burry L; Steinberg M; Ricciuto DR; Fernandes T; Chiu A; Raybardhan S; Science M; Fernando E; Tomlinson G; Bell CM; Morris AM
J Antimicrob Chemother; 2015 May; 70(5):1539-46. PubMed ID: 25614044
[TBL] [Abstract][Full Text] [Related]
26. Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis.
Lee BJ; Wang SK; Constantino-Corpuz JK; Apolinario K; Nadler B; McDanel JS; Scheetz MH; Rhodes NJ
Int J Antimicrob Agents; 2019 Mar; 53(3):225-233. PubMed ID: 30476572
[TBL] [Abstract][Full Text] [Related]
27. Retrospective Analysis of Adverse Drug Events Between Nafcillin Versus Cefazolin for Treatment of Methicillin-Susceptible
Chan L; Chan-Tompkins NH; Como J; Guarascio AJ
Ann Pharmacother; 2020 Jul; 54(7):662-668. PubMed ID: 31888347
[No Abstract] [Full Text] [Related]
28. Comparison of penicillins (penicillin G and ampicillin) and cefazolin as a definitive therapy against penicillin-susceptible Staphylococcus aureus (PSSA) bacteremia in Japan: a retrospective cohort study.
Moriyama Y; Ishikane M; Mezaki K; Ohmagari N
J Infect Chemother; 2020 Apr; 26(4):358-362. PubMed ID: 31822451
[TBL] [Abstract][Full Text] [Related]
29. Flucloxacillin and cefazolin for treatment of Staphylococcus aureus bloodstream infection.
Schmidt-Hellerau K; Breuninger M; Kessel J; Vehreschild MJGT; Paul G; Reusch J; Jung N; Hellmich M; Fätkenheuer G
Infection; 2024 Jun; 52(3):1159-1163. PubMed ID: 38296936
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.
Schweizer ML; Furuno JP; Harris AD; Johnson JK; Shardell MD; McGregor JC; Thom KA; Cosgrove SE; Sakoulas G; Perencevich EN
BMC Infect Dis; 2011 Oct; 11():279. PubMed ID: 22011388
[TBL] [Abstract][Full Text] [Related]
31. Cefazolin versus cloxacillin as definitive antibiotic therapy for methicillin-susceptible Staphylococcus aureus spinal epidural abscess: a retrospective cohort study.
Bai AD; Findlater A; Irfan N; Singhal N; Loeb M
Int J Antimicrob Agents; 2021 Nov; 58(5):106429. PubMed ID: 34469802
[TBL] [Abstract][Full Text] [Related]
32. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial.
Cheng MP; Lawandi A; Butler-Laporte G; Paquette K; Lee TC
Trials; 2018 May; 19(1):297. PubMed ID: 29843781
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia.
Lee S; Kwon KT; Kim HI; Chang HH; Lee JM; Choe PG; Park WB; Kim NJ; Oh MD; Song DY; Kim SW
Microb Drug Resist; 2014 Dec; 20(6):568-74. PubMed ID: 25000230
[TBL] [Abstract][Full Text] [Related]
34. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?
Lee S; Choe PG; Song KH; Park SW; Kim HB; Kim NJ; Kim EC; Park WB; Oh MD
Antimicrob Agents Chemother; 2011 Nov; 55(11):5122-6. PubMed ID: 21825299
[TBL] [Abstract][Full Text] [Related]
35. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.
Rao SN; Rhodes NJ; Lee BJ; Scheetz MH; Hanson AP; Segreti J; Crank CW; Wang SK
Antimicrob Agents Chemother; 2015 Sep; 59(9):5232-8. PubMed ID: 26077253
[TBL] [Abstract][Full Text] [Related]
36. Improving Clinical Outcomes in Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy.
Blumenthal KG; Parker RA; Shenoy ES; Walensky RP
Clin Infect Dis; 2015 Sep; 61(5):741-9. PubMed ID: 25991471
[TBL] [Abstract][Full Text] [Related]
37. Ceftriaxone versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia.
Mohamed A; Bennett N; Ploetz J; Aragon L; Kennedy K; Boyd S
Int J Antimicrob Agents; 2022 Sep; 60(3):106632. PubMed ID: 35787919
[TBL] [Abstract][Full Text] [Related]
38. Clinical Outcomes of Daptomycin Versus Anti-Staphylococcal Beta-Lactams in Definitive Treatment of Methicillin-susceptible Staphylococcus aureus Bloodstream Infections.
Agnello S; Wardlow LC; Reed E; Smith JM; Coe K; Day SR
Int J Antimicrob Agents; 2021 Aug; 58(2):106363. PubMed ID: 34033912
[TBL] [Abstract][Full Text] [Related]
39. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort.
Herrera-Hidalgo L; Muñoz P; Álvarez-Uría A; Alonso-Menchén D; Luque-Marquez R; Gutiérrez-Carretero E; Fariñas MDC; Miró JM; Goenaga MA; López-Cortés LE; Angulo-Lara B; Boix-Palop L; de Alarcón A;
Int J Infect Dis; 2023 Dec; 137():134-143. PubMed ID: 37926195
[TBL] [Abstract][Full Text] [Related]
40. Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation.
Antosz K; Battle S; Chang J; Scheetz MH; Al-Hasan M; Bookstaver PB
Pharmacotherapy; 2023 Jan; 43(1):85-95. PubMed ID: 36521869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
